AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3912619 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 263
Study 31386576 — intervention group
Group type: EXPERIMENTAL
Intervention: Double documentation system (electronic and paper records)
Number of subjects: 904
Study 31386576 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation for legal protection
Number of subjects: 904
Study 31386576 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation as a legal obligation
Number of subjects: 904
Study 31386576 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation to track patient progress
Number of subjects: 904
Study 31386576 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to medical documentation
Number of subjects: 904
Study 31386576 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in documentation practices
Number of subjects: 904
Study 28687908 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 12
Study 28687908 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS
Number of subjects: 12
Study 28687908 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study 25851776 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate loading (CHL) drinks consumed 12 and 2 hours presurgery, and immediate postoperative peripheral parenteral nutrition.
Number of subjects: 203
Study 25851776 — intervention group
Group type: COMPARATOR
Intervention: Standard management (control group).
Number of subjects: 203
Study 24098072 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil
Number of subjects: 45
Study 24098072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sardine oil
Number of subjects: 45
Study 24098072 — intervention group
Group type: COMPARATOR
Intervention: Medium-chain triglycerides
Number of subjects: 45
Study 20926754 — intervention group
Group type: EXPERIMENTAL
Intervention: BG9928 (0.03 mg/kg)
Number of subjects: 33
Study 20926754 — intervention group
Group type: EXPERIMENTAL
Intervention: BG9928 (0.3 mg/kg)
Number of subjects: 33
Study 20926754 — intervention group
Group type: EXPERIMENTAL
Intervention: BG9928 (1.0 mg/kg)
Number of subjects: 33
Study 20926754 — intervention group
Group type: EXPERIMENTAL
Intervention: BG9928 (3.0 mg/kg)
Number of subjects: 33
Study 20926754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 19809502 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Lasting Insecticidal Hammocks (LLIH) distributed to the intervention group.
Number of subjects: 18646
Study 19809502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLIH).
Number of subjects: 18646
Study 16954936 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration contrast medium (370 mg I/mL)
Number of subjects: 100
Study 16954936 — intervention group
Group type: COMPARATOR
Intervention: Low-concentration contrast medium (300 mg I/mL)
Number of subjects: 100
Study 15250771 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple treatments with indocyanine green (ICG) and near infrared (NIR) diode laser phototherapy
Number of subjects: 12
Study 15250771 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatment with indocyanine green (ICG) and near infrared (NIR) diode laser phototherapy
Number of subjects: 12
Study 11346270 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole prophylaxis
Number of subjects: 298
Study 11346270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 9171066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose m-BACOD with GM-CSF (n=98)
Number of subjects: 198
Study 9171066 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose m-BACOD with GM-CSF (n=94)
Number of subjects: 198
Study 7954259 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB2 strong staining (3+)
Number of subjects: 354
Study 7954259 — intervention group
Group type: COMPARATOR
Intervention: All other patients (negative, weak (1+), moderate (2+))
Number of subjects: 354
Study 2444513 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef
Number of subjects: 30
Study 2444513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 30
Study 2444513 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 31436659 — intervention group
Group type: EXPERIMENTAL
Intervention: FHL transfer using interference screw fixation
Number of subjects: 60
Study 31436659 — intervention group
Group type: EXPERIMENTAL
Intervention: FHL transfer
Number of subjects: 60
Study 27529533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination of the first metatarsophalangeal joints (MTPJs) and knee joints
Number of subjects: 62
Study 27529533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination of the first metatarsophalangeal joints (MTPJs) and knee joints in high SUA subgroup
Number of subjects: 62
Study 27529533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination of the first metatarsophalangeal joints (MTPJs) and knee joints in low SUA subgroup
Number of subjects: 62
Study 25128434 — intervention group
Group type: EXPERIMENTAL
Intervention: Video condition
Number of subjects: 256
Study 25128434 — intervention group
Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 256
Study 24075427 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin in balanced salt solution (BSS)
Number of subjects: 51
Study 24075427 — intervention group
Group type: COMPARATOR
Intervention: Standard BSS
Number of subjects: 51
Study 21703613 — intervention group
Group type: COMPARATOR
Intervention: CEE + PL
Number of subjects: 24
Study 21703613 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MPA
Number of subjects: 24
Study 21703613 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MP
Number of subjects: 24
Study 19327749 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopic eyes
Number of subjects: 37
Study 19327749 — intervention group
Group type: COMPARATOR
Intervention: Fellow eyes
Number of subjects: 37
Study 19327749 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of RNFL thickness
Number of subjects: 37
Study 19327749 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest variability
Number of subjects: 37
Study 16424718 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine (0.4 g x kg body weight(-1) x 24 hrs(-1))
Number of subjects: 40
Study 16424718 — intervention group
Group type: COMPARATOR
Intervention: Control (without alanyl-glutamine)
Number of subjects: 40
Study 15591746 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyl-2-cyanoacrylate adhesive
Number of subjects: 46
Study 15591746 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene mesh with 3/0 Dexon sutures
Number of subjects: 46
Study 12829670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose radiotherapy (50.4 Gy in 28 fractions)
Number of subjects: 203
Study 12829670 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose radiotherapy (64.8 Gy in 36 fractions)
Number of subjects: 203
Study 12829670 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (both doses)
Number of subjects: 203
Study 9607553 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal treatment (NHT) with leuprolide plus cyproterone acetate
Number of subjects: 0
Study 8567545 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-breath hyperoxic hypercapnic stimulus (0.01 liter of CO2 in O2)
Number of subjects: 9
Study 8567545 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-breath increase of 1 Torr in end-tidal PCO2
Number of subjects: 9
Study 8567545 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of the closed-loop VI response
Number of subjects: 9
Study 1369846 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty with 5 different types of prostheses
Number of subjects: 38
Study 319424 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin + aspirin (150 mg indomethacin daily, 1500 mg aspirin daily)
Number of subjects: 31
Study 319424 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (150 mg daily)
Number of subjects: 31
Study 319424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31339011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/day)
Number of subjects: 135
Study 31339011 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (2 mg/day)
Number of subjects: 135
Study 31303277 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 28
Study 31303277 — intervention group
Group type: COMPARATOR
Intervention: Sham-RMT
Number of subjects: 28
Study 29258520 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise session (energy expenditure of 250 Kcal, light intensity)
Number of subjects: 66
Study 29258520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 66
Study 27777509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation (CI)
Number of subjects: 120
Study 27777509 — intervention group
Group type: COMPARATOR
Intervention: Bone Conduction Devices (BCD)
Number of subjects: 120
Study 27777509 — intervention group
Group type: COMPARATOR
Intervention: Contralateral Routing of Sound systems (CROS)
Number of subjects: 120
Study 24142686 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 81
Study 24142686 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 81
Study 22515416 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg
Number of subjects: 293
Study 22515416 — intervention group
Group type: COMPARATOR
Intervention: ramipril 5 mg
Number of subjects: 293
Study 19717887 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-implantation ultrasound (US) imaging
Number of subjects: 30
Study 19717887 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative plans on US
Number of subjects: 30
Study 19717887 — intervention group
Group type: COMPARATOR
Intervention: CT images performed 4 weeks post-operatively
Number of subjects: 30
Study 17459221 — intervention group
Group type: COMPARATOR
Intervention: Ulinastatin (300 K units per day) + thymosin alpha1 (Maipuxin, 1.6 mg per day) for 7 days (treatment group 1)
Number of subjects: 433
Study 17459221 — intervention group
Group type: COMPARATOR
Intervention: Double dosage of Ulinastatin and thymosin alpha1 (treatment group 2)
Number of subjects: 433
Study 15141331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DFMO at 100 mg/kg body weight every 6 h for 14 days
Number of subjects: 25
Study 15141331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DFMO at 125 mg/kg body weight every 6 h for 14 days
Number of subjects: 25
Study 15141331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DFMO at 100 mg/kg
Number of subjects: 25
Study 15141331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DFMO at 125 mg/kg
Number of subjects: 25
Study 12026026 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in breastfeeding mothers and infants
Number of subjects: 0
Study 12026026 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin A supplementation during pregnancy
Number of subjects: 0
Study 12026026 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved infant vitamin A status
Number of subjects: 0
Study 9827708 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM-P regimen (5-FU, doxorubicin, mitomycin C, and OK-432)
Number of subjects: 99
Study 9827708 — intervention group
Group type: COMPARATOR
Intervention: FAM regimen (5-FU, doxorubicin, mitomycin C)
Number of subjects: 99
Study 9827708 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM-P regimen
Number of subjects: 99
Study 9827708 — intervention group
Group type: COMPARATOR
Intervention: FAM regimen
Number of subjects: 99
Study 7547226 — intervention group
Group type: EXPERIMENTAL
Intervention: uPA levels and macrophage counts in tumour tissue
Number of subjects: 42
Study 30417662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rivaroxaban 2.5 mg twice‐daily and aspirin 100 mg daily
Number of subjects: 27395
Study 30417662 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice‐daily alone
Number of subjects: 27395
Study 30417662 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg daily alone
Number of subjects: 27395
Study 26718418 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexican diet
Number of subjects: 53
Study 26718418 — intervention group
Group type: COMPARATOR
Intervention: US diet
Number of subjects: 53
Study 25148458 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs) therapy
Number of subjects: 1071
Study 25148458 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional validation of genes (CTSZ-SLMO2-ATP5E, TRAM2-TMEM14A, MAP4K4)
Number of subjects: 1071
Study 25148458 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP genotype-dependent variation in E2 induction
Number of subjects: 1071
Study 22166167 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-flap surgery (OF)
Number of subjects: 32
Study 22166167 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine bone mineral (BBM)
Number of subjects: 32
Study 19955739 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of vitamins (adherence >90% to <99%)
Number of subjects: 3357
Study 19955739 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of vitamins (adherence >=99%)
Number of subjects: 3357
Study 19955739 — intervention group
Group type: COMPARATOR
Intervention: Low adherence (<65%)
Number of subjects: 3357
Study 19955739 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence (>=80%)
Number of subjects: 3357
Study 19955739 — intervention group
Group type: COMPARATOR
Intervention: Poor adherence (<80%)
Number of subjects: 3357
Study 19033818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 10742
Study 17190130 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 hours PVC
Number of subjects: 221
Study 17190130 — intervention group
Group type: COMPARATOR
Intervention: 96 hours PVC
Number of subjects: 221
Study 17190130 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours PVC
Number of subjects: 221
Study 17190130 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hours PVC
Number of subjects: 221
Study 17190130 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and intravenous antibiotherapy
Number of subjects: 221
Study 17190130 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 221
Study 17190130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous steroids
Number of subjects: 221
Study 17190130 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal medicine/infectious diseases department
Number of subjects: 221
Study 12811568 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant work rate exercise test (0 W followed by 50-W step)
Number of subjects: 21
Study 12811568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp exercise testing (15 W. min(‐1) ramp)
Number of subjects: 21
Study 12811568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical DeltaVO2/DeltaWR derived from VO2 step response
Number of subjects: 21
Study 12811568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical and measured DeltaVO2/DeltaWR correlation
Number of subjects: 21
Study 10781507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital eye service follow up
Number of subjects: 403
Study 10781507 — intervention group
Group type: COMPARATOR
Intervention: Community optometrists follow up
Number of subjects: 403
Study 8834905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone diluted in sterile water
Number of subjects: 0
Study 8834905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone diluted in 1% lidocaine
Number of subjects: 0
Study 8834905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone diluted in buffered lidocaine
Number of subjects: 0
Study 1336526 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 mmol/day)
Number of subjects: 18
Study 1336526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3966997 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolaemic haemodilution
Number of subjects: 38
Study 3966997 — intervention group
Group type: COMPARATOR
Intervention: Control (panretinal photocoagulation only)
Number of subjects: 38
Study 30115553 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe
Number of subjects: 107
Study 30115553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 26779855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering clopidogrel discontinuation during a two‐week period (n = 25)
Number of subjects: 49
Study 26779855 — intervention group
Group type: COMPARATOR
Intervention: Abrupt clopidogrel cessation (n = 24)
Number of subjects: 49
Study 25561347 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching (biopsy procedure twice)
Number of subjects: 387
Study 25561347 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 387
Study 25561347 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching (in subgroup with two or more previous failures)
Number of subjects: 387
Study 24386434 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtering facepiece respirators with 3 mm H2O pressure drop
Number of subjects: 10
Study 24386434 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtering facepiece respirators with 6 mm H2O pressure drop
Number of subjects: 10
Study 24386434 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtering facepiece respirators with 9 mm H2O pressure drop
Number of subjects: 10
Study 20061360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (haemoglobin A(1C) <6.0%)
Number of subjects: 10209
Study 20061360 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control (haemoglobin A(1C) 7.0-7.9%)
Number of subjects: 10209
Study 20061360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 10209
Study 20061360 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 10209
Study 20061360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 10209
Study 19031507 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour training program on breastfeeding promotion for health providers
Number of subjects: 1491
Study 15983147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg added to lidocaine infiltration
Number of subjects: 40
Study 15983147 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg injected subcutaneously in the contralateral abdominal wall (Control)
Number of subjects: 40
Study 15983147 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 12923398 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylate-lysin (500 mg intravenously)
Number of subjects: 40
Study 12923398 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (20 mg intravenously)
Number of subjects: 40
Study 12923398 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside (1.6, 3.2, or 4.0 microg/min)
Number of subjects: 40
Study 10540095 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 397
Study 10540095 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 397
Study 10540095 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg plus dexamethasone 5 mg
Number of subjects: 397
Study 9103076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell free staphylococcal vaccine
Number of subjects: 100
Study 9103076 — intervention group
Group type: COMPARATOR
Intervention: Commercial preparation of staphylococcal antiphagin (Control Group 1)
Number of subjects: 100
Study 9103076 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods without vaccines (Control Group 2)
Number of subjects: 100
Study 2070135 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell transfusions shortly before BMT
Number of subjects: 969
Study 2070135 — intervention group
Group type: COMPARATOR
Intervention: No transfusion before BMT
Number of subjects: 969
Study 6678385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of clonidine hydrochloride (Group 1)
Number of subjects: 24
Study 6678385 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of clonidine hydrochloride (Group 2)
Number of subjects: 24
Study 30472992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment (IPT) including whole mouth subgingival scaling, surgical periodontal therapy (if good oral hygiene), and supportive periodontal therapy every 3 months.
Number of subjects: 264
Study 30472992 — intervention group
Group type: COMPARATOR
Intervention: Control periodontal treatment (CPT) including supra-gingival scaling and polishing at the same timepoints as in the IPT group.
Number of subjects: 264
Study 30472992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment (IPT)
Number of subjects: 264
Study 30472992 — intervention group
Group type: COMPARATOR
Intervention: Control periodontal treatment (CPT)
Number of subjects: 264
Study 26727413 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist MI‐consistent behaviors (MICO)
Number of subjects: 174
Study 26727413 — intervention group
Group type: EXPERIMENTAL
Intervention: Change talk strength (CTS)
Number of subjects: 174
Study 26727413 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist experience in MI
Number of subjects: 174
Study 26727413 — intervention group
Group type: EXPERIMENTAL
Intervention: Client alcohol problem severity
Number of subjects: 174
Study 24822238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 40
Study 24822238 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg
Number of subjects: 40
Study 22691021 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness treatment (n=41)
Number of subjects: 112
Study 22691021 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-reduction treatment (n=39)
Number of subjects: 112
Study 22691021 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n=32)
Number of subjects: 112
Study 22691021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 112